MitoRx Therapeutics
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
900 Garsington Rd, Oxford, Oxfordshire, ...Phone Number
+44 1235838631Website
www.mitorxtherapeutics.comRevenue
<$5 MillionIndustry
About MitoRx Therapeutics
MitoRx Therapeutics Org Chart
Is MitoRx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if MitoRx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at MitoRx Therapeutics
Earning: See what the market has to say on MitoRx Therapeutics recently announced quarterly report
Click to see if MitoRx Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once MitoRx Therapeutics has new funding data
Check out if MitoRx Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when MitoRx Therapeutics launches new products
MitoRx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to MitoRx Therapeutics
Compare insights from companies similar to MitoRx Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MitoRx Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MitoRx Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MitoRx Therapeutics.
MitoRx Therapeutics financials insights
Gather financial insights about MitoRx Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Angel/Seed
$5M
MitoRx Therapeutics Tech Stack
A closer look at the technologies used by MitoRx Therapeutics
Most Recent Scoops
MitoRx Therapeutics News & Media
MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions
Harwell Oxford, UK – 8 June 2026: MitoRx Therapeutics (“MitoRx”), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, announces preclinical data for its lead asset, MTRX31, was presented at the American Diabetes Association’s 2026 Scientific Sessions (ADA 2026), taking place in New Orleans, Louisiana from 5-8 June.MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions
Harwell, Oxford, UK – 27 May 2026: MitoRx Therapeutics (“MitoRx”), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, announces that preclinical data for its lead asset MTRX31 will be presented at the American Diabetes Association’s 2026 Scientific Sessions (ADA 2026), taking place in New Orleans, Louisiana from 5-8 June.MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director
OXFORD, United Kingdom, Jan. 09, 2025 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor therapeutics (mtH2SD) in obesity-related disorders and myopathies announces the appointments of Dr. Lubor Gaal as Chief Business Officer (CBO) and Stacey Massey as Finance Director. These key leadership additions reinforce MitoRx’s commitment to advancing its innovative programs including its obesity program offering weightMitoRx Therapeutics Announces Publication Showing Mitochondrial Sulfide Donor AP39 Significantly Alleviates Obesity
OXFORD, United Kingdom, Oct. 10, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor therapeutics (mtH2SD) in obesity-related disorders and myopathies announces a publication in Elsevier’s prestigious biomedical sciences journal Pharmacological Research. The work led by collaborators at Jagiellonian University Medical College showed that in a preclinical mouse study involving high-fat diet (HFD)-induced obe
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MitoRx Therapeutics
MitoRx Therapeutics specializes in developing first-in-class small molecule therapeutics that modulate mitochondrial metabolism, primarily targeting obesity and other cardiometabolic diseases. Their innovative approach aims to facilitate weight loss while preserving lean mass, utilizing mitochondrial-targeted compounds that have shown efficacy in v... Read More